Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

Launched by HK INNO.N CORPORATION · Apr 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a chemotherapy treatment called FOLFIRINOX in patients who have had surgery for pancreatic cancer. Specifically, it aims to see how well this treatment works over time, focusing on two important outcomes: disease-free survival (how long patients live without the cancer returning) and overall survival (how long patients live after treatment). The trial is currently looking for participants who are over 19 years old and are planning to receive FOLFIRINOX after their surgery. Eligible participants should be in good overall health and have had a specific type of surgery to remove the cancer.

If you decide to join this trial, you will receive FOLFIRINOX as part of your post-surgery treatment plan. The study will monitor your health and the effects of the treatment over time. It's important to note that some individuals may not be eligible, especially those with certain health issues or previous allergic reactions to FOLFIRINOX. This trial could provide valuable information that helps improve treatment for future pancreatic cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age over 19 at the time of obtaining the informed consent form
• • Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
• • ECOG 0 or 1
• • Scheduled to RO or R1 resection
• • Organ function capable of chemotherapy
• Exclusion Criteria:
• • FOLFIRINOX contraindications among the drug approval requirements
• • Palliative Therapy
• • Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX